Clinical trial
Randomized, Open-label, Phase 3 Study to Evaluate the Efficacy and Safety of LIB003, Evolocumab and Alirocumab in CVD Patients, or at High Risk for CVD, on Stable Lipid-Lowering Therapy Requiring Additional LDL-C Reduction (LIBerate-H2H)
NCT04790513 is registered in ClinicalTrials.gov with LIB Therapeutics LLC as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Randomized, Open-label, Phase 3 Study to Evaluate the Efficacy and Safety of LIB003, Evolocumab and Alirocumab in CVD Patients, or at High Risk for CVD, on Stable Lipid-Lowering Therapy Requiring Additional LDL-C Reduction (LIBerate-H2H)
- Lead sponsor
- LIB Therapeutics LLC
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- April 22, 2021
- Completion date
- December 31, 2022
- Enrollment
- 204 (actual)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.